Compare Berkshire Hathaway Inc Class B (BRK.B) vs Summit Therapeutics Inc (SMMT) Price & Performance

Berkshire Hathaway Class B shares (BRK.B) trade at $516.22, down 2.54% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. The stock shows strong technical momentum with key support at $513 and resistance at $522.

The outlook remains favorable given strong institutional support and bullish technicals, though risks include market volatility and economic sensitivity. Upside potential hinges on continued earnings stability and strategic acquisitions under Warren Buffett's leadership.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.